Cervicovaginal colposcopic lesions associated with 5 nonoxynol-9 vaginal spermicide formulations

American Journal of Obstetrics and Gynecology

Volumn 198, Issue 1, 2008, Pages 32.e1-32.e7

  Harwood, Bryna ^a   Meyn, Leslie A ^b   Ballagh, Susan A ^c   Raymond, Elizabeth G ^d   Archer, David F ^c   Creinin, Mitchell D ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

colposcopy; epithelial disruption; nonoxynol 9; vaginal spermicides

Indexed keywords

ADVANTAGE 24; NONOXINOL 9; ORTHO OPTIONS CONCEPTROL GEL; SPERMICIDAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COLPOSCOPY; CONDOM; CONFIDENCE INTERVAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; EDEMA; ERYTHEMA; FEMALE; FOLLOW UP; GEL; HUMAN; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SUPPOSITORY; UTERINE CERVIX DISEASE; VAGINA DISEASE;

EID: 37349113368     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.05.020     Document Type: Article

References (22)

1. Trussell J. Contraceptive failure in the United States. Contraception 70 (2004) 89-96
2. Henshaw S. Unintended pregnancy in the United States. Fam Plann Persp 30 (1998) 24-29
3. Mosher W., Martinez G., Chandra A., Abma J., and Willson S. Use of contraception and use of family planning services in the United States: 1982-2002 (2004), National Center for Health Statistics, Hyattsville, MD
4. Niruthisard S., Roddy R.E., and Chutivongse S. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis 18 (1991) 176-179
5. Rustomjee R., Abdool Karim Q., Abdool Karim S.S., Laga M., and Stein Z. Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. AIDS 13 (1999) 1511-1515
6. Roddy R.E., Cordero M., Cordero C., and Fortney J.A. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS 4 (1993) 165-170
7. WHO. Manual for the standardization of colposcopy for the evaluation of vaginally administered product (1995), World Health Organization Global Programme on AIDS, Geneva WHO/GPA/RID/95.10
8. Raymond E.G., Lien Chen P., Luoto J., and Spermicide Trial Group. Contraceptive effectiveness and Safety of five nonoxynol-9 spermicides: a randomized trial. Obstet Gynecol 103 (2004) 430-439
9. CONRAD/WHO. Manual for the standardization of colposcopy for the evaluation of vaginal products, update 2000 (2000), CONRAD/WHO, Geneva CONRAD/2000.1, WHO/RHR/00.11.
10. Hardin J.W., and Hilbe J.M. Generalized estimating equations (2003), Chapman & Hall/CRC, Boca Raton, FL
11. Kilmarx P.H., Limpakarnjanarat K., Supawitkul S., et al. Mucosal disruption due to use of a widely-distributed commercial vaginal product: potential to facilitate HIV transmission. AIDS 12 (1998) 767-773
12. Schreiber C.A., Meyn L.A., Creinin M.D., Barnhart K.T., and Hillier S.L. Effects of long-term use of nonoxynol-9 on vaginal flora. Obstet Gynecol 107 (2006) 136-143
13. Van Damme L., Chandeying V., Ramjee G., et al. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group. AIDS 14 (2000) 85-88
14. Stafford M.K., Ward H., Flanagan A., et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 17 (1998) 327-331
15. Mauck C.K., Baker J.M., Barr S.P., Abercrombie T.J., and Archer D.F. A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9. Postcoital testing and colposcopy. Contraception 56 (1997) 89-96
16. Mauck C.K., Baker J.M., Barr S.P., Johanson W.M., and Archer D.F. A phase I comparative study of three contraceptive vaginal films containing nonoxynol-9: postcoital testing and colposcopy. Contraception 56 (1997) 97-102
17. Poindexter III A.N., Levine H., Sangi-Haghpeykar H., Frank M.L., Grear A., and Reeves K.O. Comparison of spermicides on vulvar, vaginal, and cervical mucosa. Contraception 53 (1996) 147-153
18. Watts D.H., Rabe L., Krohn M.A., Aura J., and Hillier S.L. The effects of three nonoxynol-9 preparations on vaginal flora and epithelium. J Infect Dis 180 (1999) 426-437
19. Van Damme L., Niruthisard S., Atisook R., et al. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS 12 (1998) 433-437
20. Ladipo O.A., De Castro M.P., Filho L.C., et al. A new vaginal antimicrobial contraceptive formulation: phase I clinical pilot studies. Contraception 62 (2000) 91-97
21. Joshi S., Joglekar N., Ghate M., et al. Phase I safety and preliminary acceptability of nonoxynol-9 vaginal pessary as a vaginal microbicide in low risk women in Pune, India. Indian J Med Res 117 (2003) 152-157
22. Creatsas G., Elsheikh A., and Colin P. Safety and tolerability of the new contraceptive sponge Protectaid. Eur J Contracep Reprod Health Care 7 (2002) 91-95